作者: Holger Hof , Angelika Hoess , Dieter Oetzel , Jürgen Debus , Klaus Herfarth
DOI: 10.1007/S00066-007-1724-Z
关键词:
摘要: Stereotactic treatment approaches lead to a significant reduction of irradiated volumes, which should make pulmonary targets more accessible radiotherapy. Between May 1997 and December 2005, 61 patients received stereotactic single-dose dose for 71 metastases. Doses the isocenter ranged from 12 30 Gy. Survival local tumor control rates were evaluated prospectively. After median follow-up period 14 months actuarial overall survival was 78.4%, 65.1%, 47.8% 12, 24, 36 after therapy, respectively. There significantly better (p = 0.023) not developing further metastases during follow-up. The progression-free rate 88.6%, 73.7%, 63.1% therapy. Although majority (70.4%) developed perifocal normal-tissue changes, these related clinically relevant toxicities. radiotherapy is feasible, safe effective option solitary in with contraindications surgery or palliation symptomatic